1.1 | Scope of the Report |
1.2 | Market segmentation |
1.3 | Research Methodology |
1.3.1 | Data Triangulation |
1.3.2 | Key Data Points From Primary Sources |
1.3.3 | Key Data Points From Secondary Sources |
1.3.4 | Secondary Data Sources |
1.3.5 | Top-Down Approach (Segmental Analysis) |
1.3.6 | Bottom-Up Approach (Segmental Analysis) |
1.4 | Assumptions and Limitations |
1.5 | Data and Prediction Modelling |
A quick peek into the report
Table of Contents
Report Scope & Methodology
Market Overview
2.1 | Introduction |
2.2 | Overview of Liquid Biopsy Techniques and Applications |
2.3 | Historical trends |
2.4 | Comparative Analysis of Tissue Biopsy and Liquid Biopsy |
Market Dynamics
3.1 | Promoting and Inhibiting Factors of Liquid Biopsy Market Growth |
3.2 | Drivers |
3.3 | Restraints |
3.4 | Opportunities |
Competitive Insights
4.1 | Share of Key Development and Strategies |
4.2 | Competitive Landscape |
4.3 | Market Share Analysis |
4.4 | Industry Attractiveness |
4.4.1 | Bargaining Power of Suppliers |
4.4.2 | Bargaining Power of Buyers |
4.4.3 | Threat of New Entrants |
4.4.4 | Threat of Substitute Products |
4.4.5 | Intensity of Competitive Rivalry |
Global Liquid Biopsy Market, by Product
5.1 | Overview |
5.2 | Kits and Consumables |
5.3 | Instruments |
5.4 | Services |
Global Liquid Biopsy Market, by Type of Biomarker
6.1 | Overview |
6.2 | Circulating Tumor Cell (CTC) |
6.3 | Circulating Tumor DNA (ctDNA) |
6.4 | Extracellular Vesicles (EVs) |
6.5 | Other Types of Biomarkers |
Global Liquid Biopsy Market, by Cancer Type
7.1 | Liquid Biopsy's Role in Cancer Detection: An Overview |
7.2 | Liquid Biopsy: Role in Lung Cancer Diagnosis |
7.3 | Liquid Biopsy: Role in Breast Cancer Diagnosis |
7.4 | Liquid Biopsy: Role in Colorectal Cancer Diagnosis |
7.5 | Liquid Biopsy: Role in Prostate Cancer Diagnosis |
7.6 | Liquid Biopsy: Role in Liver Cancer Diagnosis |
7.7 | Liquid Biopsy: Role in Other Cancer Diagnosis |
Global Liquid Biopsy Market, by End User
8.1 | Overview |
8.2 | Reference Laboratories |
8.3 | Hospitals and Physician Laboratories |
8.4 | Academic and Research Centers |
8.5 | Other End Users |
Global Liquid Biopsy Market, by Geography
9.1 | Overview |
9.2 | North America |
9.2.1 | U.S. |
9.2.2 | Canada |
9.3 | Europe |
9.3.1 | U.K. |
9.3.2 | Germany |
9.3.3 | France |
9.3.4 | Rest of Europe |
9.4 | Asia Pacific |
9.4.1 | China |
9.4.2 | Japan |
9.4.3 | India |
9.4.4 | Rest of the Asia Pacific |
9.5 | Rest of the World |
Company Profile
10.1 | Adaptive Biotechnologies |
10.1.1 | Overview |
10.1.2 | Adaptive Biotechnologies: Corporate Summary |
10.1.3 | Adaptive Biotechnologies: SWOT Analysis |
10.2 | ANGLE plc |
10.2.1 | Overview |
10.2.2 | Financials |
10.2.2.1 | Financial Summary |
10.2.3 | ANGLE plc: SWOT Analysis |
10.3 | Biocept, Inc. |
10.3.1 | Overview |
10.3.2 | Financials |
10.3.2.1 | Financial Summary |
10.3.3 | Biocept, Inc.: SWOT Analysis |
10.4 | Bio-Rad Laboratories, Inc. |
10.4.1 | Overview |
10.4.2 | Bio-Rad Laboratories, Inc.: Product Portfolio |
10.4.3 | Financials |
10.4.3.1 | Financial Summary |
10.4.4 | Bio-Rad Laboratories, Inc.: SWOT Analysis |
10.5 | CareDx, Inc. |
10.5.1 | Overview |
10.5.2 | Financials |
10.5.2.1 | Financial Summary |
10.5.3 | CareDx, Inc.: SWOT Analysis |
10.6 | Cynvenio Biosystems, Inc. |
10.6.1 | Overview |
10.6.2 | Cynvenio Biosystems, Inc.: Product Portfolio |
10.6.3 | Corporate Summary |
10.6.4 | Cynvenio Biosystems, Inc.: SWOT Analysis |
10.7 | Epic Sciences, Inc. |
10.7.1 | Overview |
10.7.2 | Epic Sciences, Inc.: Corporate Summary |
10.7.3 | Epic Sciences, Inc.: SWOT Analysis |
10.8 | F. Hoffmann-La Roche AG |
10.8.1 | Overview |
10.8.2 | F. Hoffmann-La Roche AG: Product Portfolio |
10.8.3 | Financials |
10.8.3.1 | Financial Summary |
10.8.4 | F. Hoffmann-La Roche AG: SWOT Analysis |
10.9 | Genomic Health, Inc. |
10.9.1 | Overview |
10.9.2 | Genomic Health, Inc.: Product Portfolio |
10.9.3 | Financials |
10.9.3.1 | Financial Summary |
10.9.4 | Genomic Health, Inc.: SWOT Analysis |
10.10 | GUARDANT HEALTH, INC |
10.10.1 | Overview |
10.10.2 | GUARDANT HEALTH, INC: Corporate Summary |
10.10.3 | GUARDANT HEALTH, INC: SWOT Analysis |
10.11 | Illumina, Inc. |
10.11.1 | Overview |
10.11.2 | Illumina, Inc.: Product Portfolio |
10.11.3 | Financials |
10.11.3.1 | Financial Summary |
10.11.4 | Illumina, Inc.: SWOT Analysis |
10.12 | JOHNSON & JOHNSON |
10.12.1 | Overview |
10.12.2 | JOHNSON & JOHNSON: Product Portfolio |
10.12.3 | Financials |
10.12.3.1 | Financial Summary |
10.12.4 | JOHNSON & JOHNSON: SWOT Analysis |
10.13 | MDxHealth, Inc. |
10.13.1 | Overview |
10.13.2 | Financials |
10.13.2.1 | Financial Summary |
10.13.3 | MDxHealth, Inc.: SWOT Analysis |
10.14 | Menarini Silicon Biosystems, Inc. |
10.14.1 | Overview |
10.14.2 | Menarini Silicon Biosystems, Inc.: Product Portfolio |
10.14.3 | Corporate Summary |
10.14.4 | Menarini Silicon Biosystems, Inc.: SWOT Analysis |
10.15 | Myriad Genetics, Inc. |
10.15.1 | Overview |
10.15.2 | Myriad Genetics, Inc.: Product Portfolio |
10.15.3 | Financials |
10.15.3.1 | Financial Summary |
10.15.4 | Myriad Genetics, Inc.: SWOT Analysis |
10.16 | Natera, Inc. |
10.16.1 | Overview |
10.16.2 | Natera, Inc.: Product Portfolio |
10.16.3 | Financials |
10.16.3.1 | Financial Summary |
10.16.4 | Natera, Inc.: SWOT Analysis |
10.17 | NeoGenomics Laboratories, Inc. |
10.17.1 | Overview |
10.17.2 | NeoGenomics Laboratories, Inc.: Product Portfolio |
10.17.3 | Financials |
10.17.3.1 | Financial Summary |
10.17.4 | NeoGenomics Laboratories, Inc.: SWOT Analysis |
10.18 | QIAGEN |
10.18.1 | Overview |
10.18.2 | QIAGEN: Product Portfolio |
10.18.3 | Financials |
10.18.3.1 | Financial Summary |
10.18.4 | QIAGEN: SWOT Analysis |
10.19 | RainDance Technologies, Inc. |
10.19.1 | Overview |
10.19.2 | RainDance Technologies, Inc.: Product Portfolio |
10.19.3 | Financials |
10.19.3.1 | Financial Summary |
10.19.4 | RainDance Technologies, Inc.: SWOT Analysis |
10.20 | Sysmex Corporation |
10.20.1 | Overview |
10.20.2 | Sysmex Corporation: Product Portfolio |
10.20.3 | Financials |
10.20.3.1 | Financial Summary |
10.20.4 | Sysmex Corporation: SWOT Analysis |
10.21 | Thermo Fisher Scientific |
10.21.1 | Overview |
10.21.2 | Thermo Fisher Scientific: Product Portfolio |
10.21.3 | Financials |
10.21.3.1 | Financial Summary |
10.21.4 | Thermo Fisher Scientific: SWOT Analysis |
10.22 | TROVAGENE, INC. |
10.22.1 | Overview |
10.22.2 | TROVAGENE, INC.: Product Portfolio |
10.22.3 | Financials |
10.22.3.1 | Financial Summary |
10.22.4 | TROVAGENE, INC.: SWOT Analysis |
List of Tables
1 | Cancer Incidence by Region, 2012 (Thousands) |
2 | Tissue Biopsy vs. Liquid Biopsy |
3 | Joint Ventures, Partnerships, Agreements and Collaborations |
4 | Product Launch |
5 | Mergers and Acquisitions |
6 | Regulatory Approval |
7 | Expansions and Others |
8 | List of Available Kits in the Market |
9 | List of Available Instruments and Platforms in the Market |
10 | List of Tests Available in the Market |
11 | Lung Cancer Incidence in Top Countries (2014-2025) |
12 | Breast Cancer Incidence in Top Countries (2014-2025) |
13 | Colorectal Cancer Incidence in Top Countries (2014-2025) |
14 | Prostate Cancer Incidence in Top Countries (2014-2025) |
15 | Liver Cancer Incidence in Top Countries (2014-2025) |
16 | Incidence Rate of Different Cancer Types, U.S. (2014-2025) |
17 | Incidence Rate of Different Cancer Types, Canada (2014-2025) |
18 | Incidence Rate of Different Cancer Types, U.K. (2014-2025) |
19 | Incidence Rate of Different Cancer Types, Germany (2014-2025) |
20 | Incidence Rate of Different Cancer Types, France (2014-2025) |
21 | Incidence Rate of Different Cancer Types, Italy (2014-2025) |
22 | Incidence Rate of Different Cancer Types, China (2014-2025) |
23 | Incidence Rate of Different Cancer Types, Japan (2014-2025) |
24 | Incidence Rate of Different Cancer Types, India (2014-2025) |
25 | Incidence Rate of Different Cancer Types, Australia (2014-2025) |
26 | Incidence Rate of Different Cancer Types, South Korea (2014-2025) |
27 | Incidence Rate of Different Cancer Types, Mexico (2014-2025) |
28 | Incidence Rate of Different Cancer Types, Turkey (2014-2025) |
29 | Incidence Rate of Different Cancer Types, Saudi Arabia (2014-2025) |
30 | Adaptive Biotechnologies: Overview |
31 | ANGLE plc: Overview |
32 | Biocept, Inc.: Overview |
33 | Bio-Rad Laboratories, Inc.: Overview |
34 | CareDx, Inc.: Overview |
35 | Cynvenio Biosystems, Inc.: Overview |
36 | Epic Sciences, Inc.: Overview |
37 | F. Hoffmann-La Roche AG: Overview |
38 | Genomic Health, Inc.: Overview |
39 | GUARDANT HEALTH, INC: Overview |
40 | Illumina, Inc.: Overview |
41 | JOHNSON & JOHNSON: Overview |
42 | MDxHealth, Inc.: Overview |
43 | Menarini Silicon Biosystems, Inc.: Overview |
44 | Myriad Genetics, Inc.: Overview |
45 | Natera, Inc.: Overview |
46 | NeoGenomics Laboratories, Inc.: Overview |
47 | QIAGEN: Overview |
48 | RainDance Technologies, Inc.: Overview |
49 | Sysmex Corporation: Overview |
50 | Thermo Fisher Scientific: Overview |
51 | TROVAGENE, INC.: Overview |
List of Figures
1 | Global Liquid Biopsy Market Revenue (2016-2025) |
2 | Global Liquid Biopsy Market Share, by Products and Services (2016) |
3 | Global Liquid Biopsy Market Share, by Products and Services (2025) |
4 | Global Liquid Biopsy Market Share, by Type of Biomarker (2016) |
5 | Global Liquid Biopsy Market Share, by Type of Biomarker (2025) |
6 | Global Liquid Biopsy Market Share, by Application (2016) |
7 | Global Liquid Biopsy Market Share, by Application (2025) |
8 | Global Liquid Biopsy Market Share, by End-User (2016) |
9 | Global Liquid Biopsy Market Share, by End-User (2025) |
10 | Liquid Biopsy Market Size, by Region |
11 | Liquid Biopsy Market Segmentation |
12 | Research Methodology |
13 | Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery |
14 | Comparative Analysis of Tissue Biopsy and Liquid Biopsy |
15 | Share of Key Development and Strategies |
16 | Market Share Analysis, by Companies (2015) |
17 | Market Share Analysis, by Companies (2016) |
18 | Porter’s Five Forces Analysis |
19 | Product Type Segmentation |
20 | Global Liquid Biopsy Market, by Product, 2016-2025 ($Million) |
21 | Global Liquid Biopsy Market Share, by Product, 2016-2025 |
22 | Global Liquid Biopsy Kits & Consumables Market, 2016-2025 |
23 | Global Liquid Biopsy Instruments Market, 2016-2025 ($Million) |
24 | Global Liquid Biopsy Services Market, 2016-2025 ($Million) |
25 | Different Biomarkers |
26 | Global Liquid Biopsy Market, by Biomarker Type, 2016-2025 ($Million) |
27 | Global liquid Biopsy Market, by Circulating Tumor Cells (CTCs), 2016-2025 ($Million) |
28 | List of Few CTC Based Kits and Instrument |
29 | Global liquid Biopsy Market, by Circulating Tumor DNA (ctDNA), 2016-2025 ($Million) |
30 | List of Few ctDNA Based Kits and Instrument |
31 | CTCs Vs ctDNA Analysis |
32 | Global liquid Biopsy Market, by Extracellular Vesicles (EVs), 2016-2025 ($Million) |
33 | Global liquid Biopsy Market, by Other Biomarkers (Cell Free DNA, etc.), 2016-2025 ($Million) |
34 | Standard Biopsy Vs Liquid Biopsy |
35 | Types of Lung Cancer |
36 | Lung Cancer Incidence Rate Statistics |
37 | List of Few Kits and Instruments for Lung Cancer Diagnosis |
38 | Types of Breast cancer |
39 | Breast Cancer Incidence Statistics |
40 | List of Few Kits and Instruments for Breast Cancer Diagnosis |
41 | Infected Colon and Rectum |
42 | List of Few Kits and Instruments for Colorectal Cancer Diagnosis |
43 | Colorectal Cancer Incidence Statistics |
44 | Prostate Cancer Incidence Statistics |
45 | List of Few Kits and Instruments for Prostate Cancer Diagnosis |
46 | Types of Liver Cancer |
47 | Liver Cancer Incidence Statistics |
48 | Global Liquid Biopsy Market Share, by End Users, 2016-2025 |
49 | Global Liquid Biopsy Market, by End Users, 2016-2025 ($Million) |
50 | Global Liquid Biopsy End User Market, Reference Laboratories, 2016-2025 ($Million) |
51 | Global Liquid Biopsy End User Market, Hospitals and Physician Laboratories, 2016-2025 ($Million) |
52 | Global Liquid Biopsy End User Market, Academic and Research Centers, 2016-2025 ($Million) |
53 | Global Liquid Biopsy End User Market, Others, 2016-2025 ($Million) |
54 | Global Liquid Biopsy Market, by Region |
55 | Global Liquid Biopsy Market Revenue, by Region (2016-2025) |
56 | Global Liquid Biopsy Market Share, by Region (2016) |
57 | Global Liquid Biopsy Market Share, by Region (2025) |
58 | North America Liquid Biopsy Market Revenue (2016-2025) |
59 | North America Liquid Biopsy Market, by Products & Services (2016-2025) |
60 | North America Liquid Biopsy Market, by Country (2016-2025) |
61 | U.S. Liquid Biopsy Market Revenue (2016-2025) |
62 | Canada Liquid Biopsy Market Revenue (2016-2025) |
63 | Europe Liquid Biopsy Market Revenue (2016-2025) |
64 | Europe Liquid Biopsy Market, by Products & Services (2016-2025) |
65 | Europe Liquid Biopsy Market, by Country (2016-2025) |
66 | U.K. Liquid Biopsy Market Revenue (2016-2025) |
67 | Germany Liquid Biopsy Market Revenue (2016-2025) |
68 | France Liquid Biopsy Market Revenue (2016-2025) |
69 | Rest of Europe Liquid Biopsy Market Revenue (2016-2025) |
70 | Asia Pacific Liquid Biopsy Market Revenue (2016-2025) |
71 | Asia Pacific Liquid Biopsy Market, by Products & Services (2016-2025) |
72 | Asia Pacific Liquid Biopsy Market, by Country (2016-2025) |
73 | China Liquid Biopsy Market Revenue (2016-2025) |
74 | Japan Liquid Biopsy Market Revenue (2016-2025) |
75 | India Liquid Biopsy Market Revenue (2016-2025) |
76 | Rest of Asia Pacific Liquid Biopsy Market Revenue (2016-2025) |
77 | Rest of the World (RoW) Liquid Biopsy Market Revenue (2016-2025) |
78 | Adaptive Biotechnologies: SWOT Analysis |
79 | ANGLE plc: Overall Financials (2014-2016) |
80 | ANGLE plc: Revenue by Region |
81 | ANGLE plc: SWOT Analysis |
82 | Biocept, Inc.: Overall Financials (2014-2016) |
83 | Biocept, Inc.: SWOT Analysis |
84 | Bio-Rad Laboratories, Inc.: Product Mapping |
85 | Bio-Rad Laboratories, Inc.: Overall Financials (2014-2016) |
86 | Bio-Rad Laboratories, Inc.: Net Revenue by Business Segment (2014-2016) |
87 | Bio-Rad Laboratories, Inc.: Revenue by Region (2014-2016) |
88 | Bio-Rad Laboratories, Inc.: SWOT Analysis |
89 | CareDx: Overall Financials (2014-2016) |
90 | CareDx, Inc.: SWOT Analysis |
91 | Cynvenio Biosystems, Inc.: Product Mapping |
92 | Cynvenio Biosystems, Inc.: SWOT Analysis |
93 | Epic Sciences, Inc.: SWOT Analysis |
94 | F. Hoffmann-La Roche AG: Product Mapping |
95 | F. Hoffmann-La Roche AG: Overall Financials (2014-2016) |
96 | F. Hoffmann-La Roche AG: Revenue By Geographical Area (2014-2016) |
97 | F. Hoffmann-La Roche AG: Revenue by Division (2014-2016) |
98 | F. Hoffmann-La Roche AG: Revenue By Diagnostics Sub-Division (2014-2016) |
99 | F. Hoffmann-La Roche AG: SWOT Analysis |
100 | Genomic Health, Inc.: Product Mapping |
101 | Genomic Health, Inc.: Overall Financials (2014-2016) |
102 | Genomic Health, Inc.: Net Revenue by Region (2014-2016) |
103 | Genomic Health, Inc.: SWOT Analysis |
104 | GUARDANT HEALTH, INC: SWOT Analysis |
105 | Illumina, Inc: Product Mapping |
106 | Illumina, Inc.: Overall Financials (2014-2016) |
107 | Illumina, Inc.: Net Revenue by Business Segment (2014-2016) |
108 | Illumina, Inc.: Revenue by Region (2014-2016) |
109 | Illumina, Inc.: SWOT Analysis |
110 | JOHNSON & JOHNSON: Product Mapping |
111 | JOHNSON & JOHNSON: Overall Financials (2014-2016) |
112 | JOHNSON & JOHNSON: Net Revenue by Business Segment (2014-2016) |
113 | JOHNSON & JOHNSON: Net Revenue by Region (2014-2016) |
114 | JOHNSON & JOHNSON: Net Revenue by Medical Devices Business Segment (2014-2016) |
115 | JOHNSON & JOHNSON: SWOT Analysis |
116 | MDxHealth, Inc.: Overall Financials (2014-2016) |
117 | MDxHealth, Inc.: SWOT Analysis |
118 | Menarini Silicon Biosystems, Inc.: Product Mapping |
119 | Menarini Silicon Biosystems, Inc.: SWOT Analysis |
120 | Myriad Genetics, Inc.: Product Mapping |
121 | Myriad Genetics, Inc.: Overall Financials (2014-2016) |
122 | Myriad Genetics, Inc.: Net Revenue by Business Segment (2014-2016) |
123 | Myriad Genetics, Inc.: SWOT Analysis |
124 | Natera, Inc.: Product Mapping |
125 | Natera, Inc.: Overall Financials (2014-2016) |
126 | Natera, Inc.: Net Revenue by Region (2014-2016) |
127 | Natera, Inc.: SWOT Analysis |
128 | NeoGenomics Laboratories, Inc.: Product Mapping |
129 | NeoGenomics Laboratories, Inc.: Overall Financials (2014-2016) |
130 | NeoGenomics Laboratories, Inc.: Net Revenue by Business Segment (2014-2016) |
131 | NeoGenomics Laboratories, Inc.: SWOT Analysis |
132 | QIAGEN: Product Mapping |
133 | QIAGEN: Overall Financials (2014-2016) |
134 | QIAGEN: Net Revenue by Region (2014-2016) |
135 | Qiagen: Revenue by Business Segments (2014-2016) |
136 | QIAGEN: SWOT Analysis |
137 | RainDance Technologies, Inc.: Product Mapping |
138 | RainDance Technologies, Inc.: Overall Financials (2014) |
139 | RainDance Technologies: Net Revenue by Region (2014) |
140 | RainDance Technologies, Inc.: SWOT Analysis |
141 | Sysmex Corporation: Product Mapping |
142 | Sysmex Corporation: Overall Financials (2014- 2016) |
143 | Sysmex Corporation: Revenue by Business Segment (2014-2016) |
144 | Sysmex Corporation: Revenue by Region(2014-2016) |
145 | Sysmex Corporation: SWOT Analysis |
146 | Thermo Fisher Scientific: Product Mapping |
147 | Thermo Fisher Scientific: Overall Financials (2014-2016) |
148 | Thermo Fisher Scientific: Net Revenue by Business Segment (2014-2016) |
149 | Thermo Fisher Scientific: Net Revenue by Region (2014-2016) |
150 | Thermo Fisher Scientific: SWOT Analysis |
151 | TROVAGENE, INC.: Product Mapping |
152 | TROVAGENE, INC.: Overall Financials (2014-2016) |
153 | TROVAGENE, INC.: SWOT Analysis |
Global Liquid Biopsy Market - Analysis and Forecast, 2017-2025
(Focus on Product Type, Therapeutic Application, End User, Market Share Analysis, Country Analysis, and Competitive Landscape)